IRON-II Study Uses 454 Sequencing to Investigate New Markers for Hematological Malignancies | GenomeWeb

A consortium of mostly European laboratories is in the midst of investigating new markers for hematological cancers using amplicon deep sequencing.

The research study, called IRON-II, for Interlaboratory Robustness of Next-generation sequencing, is supported by Roche and uses the 454 platform. A follow-on to an earlier study to test the technical performance of amplicon deep sequencing in different laboratories, the new study is investigating panels of one to 25 genes in a total of 6,000 to 8,000 retrospective samples covering five hematological malignancies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.